We further examined FAK and MEK inhibitor dose combinations across 14 GBM stem cell lines, as 7 × 7 dose combination matrices, to further investigate the FAK+MEK inhibitor synergy across a heterogeneous panel of human GBM stem cells (Figure 5). The gene discussed is PTK2; the disease is glioblastoma.